Bay Area's Igenica, Inc. Follows Genentech (RHHBY) Into Antibody-Linked Cancer Drugs
4/14/2014 7:10:07 AM
Squint a little, and it’s easy to see the first five years of Burlingame, CA-based Igenica Biotherapeutics as a speeded-up version of the evolution of biotech pioneer Genentech. Igenica’s leadership ranks are studded with Genentech alumni, including its board chair David Goeddel, a pioneer in gene expression research who was the first scientist Genentech hired. Igenica has just started its first clinical trial on an anti-cancer antibody—-following in the footsteps of Genentech, which developed groundbreaking antibody drugs such as Rituxan, a blockbuster treatment for the blood cancer non-Hodgkin’s lymphoma approved in 1997.
Help employers find you! Check out all the jobs and post your resume.
comments powered by